A geographical study of antibodies to membrane antigens of HSV‐2‐infected cells and HSV‐2‐specific antibodies in patients with cervical cancer
- 15 November 1981
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 28 (5) , 535-542
- https://doi.org/10.1002/ijc.2910280502
Abstract
Sera were obtained from patients with squamous carcinoma of the cervix from Great Britain (29), Sri Lanka (32), Malawi (27) and Sudan (27), and from controls from all countries except Sudan. Controls were matched for ethnic origin, age and social class. Sera were tested by indirect immunofluorescence (IF) for IgG and IgA antibodies to membrane antigens (MA) and IgA antibodies to VCA of HSV-2 infected cells. Compared with controls, IgA antibodies to MA (IgA anti-MA) were detected more frequently and at higher titres in all groups of patients. However, there was no significant difference in prevalence of these antibodies at titres ≥1:4 between Malawian patients and controls, although a significantly higher proportion of patients had IgA anti-MA titres of ≥1:16. In contrast, IgA anti-VCA did not distinguish patients from controls. More than 90% of both patients and controls from all countries had IgG antibodies to MA (IgA anti-MA). Malawian patients had a significantly higher geometric mean titre (GMT) of IgG anti-MA than controls and both patients and controls and significantly higher GMTs than their counterparts from other countries. The variation between herpes IgG anti-MA titres in subjects from different countries did not reflect differences in serum immunoglobulin levels and similar variations in titre were not seen in rubella and measles HAI titres. Among the patients there was a geographical variation in the prevalence of HSV-2 specific antibodies detected by ELISA, which varied from 52% among British and Sudanese patients to 73% among Malawian patients. Even when adjustment was made for possible false negative results, there were between 10 and 31% patients without HSV-2-specific antibodies, although only 2 of 103 (1.9%) patients had neither HSV-1 nor HSV-2 antibodies. The association of HSV-2 with cervical carcinoma appeared to vary with age.This publication has 29 references indexed in Scilit:
- Class‐specific antibodies (Igg and Iga) to membrane antigens of herpes simplex type‐2 infected cells in patients with cervical dysplasia and neoplasiaInternational Journal of Cancer, 1981
- EPIDEMIOLOGICAL EVIDENCE FOR TWO COMPONENTS OF CERVICAL CANCERBJOG: An International Journal of Obstetrics and Gynaecology, 1981
- Detection of Herpesvirus Type-Specific Antibody by a Micro Solid Phase Radioimmunometric AssayIntervirology, 1979
- Detection of herpes simplex virus tumor-associated antigen in uterine cervical cancer tissueGynecologic Oncology, 1978
- ELISA FOR HERPES SIMPLEX VIRUS TYPE 2 ANTIBODIESThe Lancet, 1977
- Prevalence of type-specific antibody against type 1 and type 2 herpes simplex virus in women with abnormal cervical cytology; evidence towards pre-pubertal vaccination of sero-negative female subjectsArchiv für die gesamte Virusforschung, 1977
- Detection of type-specific antibody to herpes simplex virus type 1 and 2 in human sera by complement-fixation testsArchiv für die gesamte Virusforschung, 1976
- Eb‐virus associated serology in malignant disease: antibody levels to viral capsid antigens (vca), membrane antigens (ma) and early antigens (ea) in patients with various neoplastic conditionsInternational Journal of Cancer, 1972
- EVIDENCE FOR THE EXISTENCE OF TWO FORMS OF CERVICAL CARCINOMABJOG: An International Journal of Obstetrics and Gynaecology, 1966
- Immunochemical quantitation of antigens by single radial immunodiffusionImmunochemistry, 1965